UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of
Report (Date of earliest event reported): January
16, 2007
MEDASORB
TECHNOLOGIES CORPORATION
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-51038
|
|
98-0373793
|
|
(State
or other
jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
|
of
incorporation)
|
|
File
Number)
|
|
Identification
Number)
|
7
Deer
Park Drive, Suite K, Monmouth Junction, New Jersey 08852
(Address
of principal executive office) (Zip Code)
Registrant’s
telephone number, including area code: (732)
329-8885
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2.below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
o Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13c-4(c))
| Item 5.02. |
|
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers; Compensatory Arrangements of Certain
Officers.
|
On
January 16, 2007, our Board of Directors approved the grant to David Lamadrid,
our Chief Financial Officer, of an option to purchase 150,000 shares of our
common stock at an exercise price of $1.90 (the closing price of our common
stock on the date of grant). The option is currently exercisable as to 50,000
shares, and becomes exercisable as to an additional 50,000 shares on January
16,
2008 and the remaining 50,000 shares on January 16, 2009.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
January 19, 2007
| |
|
|
| |
MEDASORB
TECHNOLOGIES CORPORATION |
|
|
|
| |
By: |
/s/ Al
Kraus |
| |
Al
Kraus, |
| |
President
and
Chief Executive Officer |